Full-Time
Develops therapies for CNS disorders
$130k - $165k/yr
Senior, Expert
Boston, MA, USA
Candidates must live in the assigned geography (New England region).
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, agitation from Alzheimer's, migraines, narcolepsy, fibromyalgia, and smoking cessation. Their main product, AXS-05, is an oral medication that acts as an NMDA receptor antagonist to help regulate mood. It has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.
Company Size
201-500
Company Stage
IPO
Headquarters
New York City, New York
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Performance Bonus
Company Equity
Axsome Therapeutics announces availability of Symbravo(R) (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
Axsome Therapeutics plans 96,000 Sq.Ft. expansion in New York City. Axsome Therapeutics plans 96,000 Sq.Ft. expansion in New York City.New York, New York — According to state and local development sources, Axsome Therapeutics plans to build out 96,000 square feet of new space in New York. The company plans to occupy the new space in New York, on or about December 1, 2025. According to the company website Axsome Therapeutics, Inc
Axsome Therapeutics (NASDAQ: AXSM) has secured a $570 million term loan and revolving credit facility with Blackstone, replacing its previous Hercules Capital term loan. The facility consists of a $500 million term loan and a $70 million revolving credit facility. The company initially drew $120 million to retire its previous loan.The new facility offers improved terms, including interest rates of SOFR plus 4.75% for the term loan and SOFR plus 4.0% for the revolving credit facility, with a 60-month interest-only period and maturity in May 2030. Additionally, Blackstone purchased $15 million of Axsome common stock at $107.14 per share. The company can access an additional $250 million at its option, with another $200 million available subject to Blackstone's approval.
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America (MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May's Mental Health Month.
Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, announced multiple presentations spanning its innovative, industry-leading psychiatry and neurology portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting, being held April 5-9 in San Diego, California.